Vaccine Against Escherichia Coli Infection

GlycoVaxyn

Status and phase: Completed; Phase 1

Conditions: E.Coli Infections

Treatments: Biological: Placebo; Biological: E.coli bioconjugate vaccine

Study type: Interventional

Funder types: Industry

Identifiers

NCT02289794

2013DR1205 (Other Identifier)

GVXN EC-4V

Details and patient eligibility

About

This Phase I multi-center placebo controlled study is conducted in healthy women with a history of recurrent urinary tract infections (UTI) aged between 18 and 70 years.

Full description

GlycoVaxyn is a Swiss company that has developed a multivalent bioconjugate vaccine for the prevention of E.coli-infections. Cystitis is the most common UTI, however kidney infections or bacteremia are possible. The E. coli bacterium is responsible for 85 % of all UTIs.

The objectives of this trial are to assess the safety and ability to elicit an immune response of the candidate vaccine as well as the effectiveness of the vaccine in the reduction in UTIs .

Enrollment: 194 patients

Sex: Female

Ages: 18 to 70 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

1. Female subjects with a history of recurrent UTI, which is defined as: ≥ 3 UTI independent episodes in the previous 12 months or ≥ 2 UTI episodes in the last 6 months. At least one UTI during the last 5 years was caused by E. coli (as single pathogen or part of polymicrobial infection) and was culture-confirmed and documented
2. Age ≥ 18 and ≤ 70 years
3. Subjects should be in a healthy state without ongoing or suspected symptomatic UTI at the screening visit and at injection day (V2)
4. General good health, without clinically significant medical history, physical examination findings or clinical laboratory abnormalities per clinical judgment of the investigator
5. Willingness to participate in the study after all aspects of the protocol have been explained and fully understood, and written informed consent form obtained

Exclusion criteria

1. History of more than 10 recurrent UTIs in the year before the screening visit
2. Use of any short-term urinary catheter within 7 days prior to screening
3. Use of any permanent catheter within 30 days prior to screening
4. History of any unresolved urinary tract diseases/abnormalities
5. Evidence of impaired immune function
6. Significant cardiovascular, liver, renal diseases and/or insufficiency
7. Uncontrolled diabetes mellitus
8. Significant abnormalities in screening results for hematology, serum chemistry or urinalysis
9. Positive test for HIV, and/or evidence of HBV or HCV
10. BMI >34
11. Previous immune stimulatory therapy for UTI prevention (such as Urovaxom®, Strovac® or Urovac®) in the last 3 months, or planned use during the study period
12. Current use of any medication known to affect immune function (e.g. corticosteroids ≥0.5 mg/kg Body weight/day)
13. Use of UTI-related vaginal estrogen treatment newly started less than 6 months before injection and continuing during the study or planned start during the active study period
14. Use of any antibiotic therapy within 1 week preceding injection
15. Planned use of post-coital antibiotics for UTI prevention during study period
16. Any vaccination planned within 30 days before and 30 days after injection
17. Participation in other clinical trials in the 60 days preceding enrolment and for the duration of the study
18. Previous treatment with immunoglobulins or blood products in the 3 months preceding the injection
19. Known hypersensitivity to any component of the vaccine
20. Presence of a significant medical or psychiatric condition that in the opinion of the investigator precludes participation in the study
21. Acute illness at the time of injection
22. Women of child bearing potential who either have a positive pregnancy test or refuse to use an effective contraception
23. Women who are lactating at any time throughout the study period
24. Subjects with an elective surgical intervention, planned during the study period
25. Any other significant finding that in the opinion of the Investigator would increase the risk of having an adverse outcome from participating in the study

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

194 participants in 2 patient groups, including a placebo group

E.coli bioconjugate vaccine

Active Comparator group

Description:

E.coli bioconjugate vaccine in saline buffer

Treatment:

Biological: E.coli bioconjugate vaccine

Placebo

Placebo Comparator group

Description:

Saline buffer

Treatment:

Biological: Placebo